What records are connected here?
- Evidence lanes
- 2
- Source years
- 7
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Not FDA-approved1Evidence: Animal and lab onlyTissue repair and wound healing · Inflammation and immune
Also called Lys-Pro-Val1
KPV is a three-amino-acid peptide (lysine, proline and valine) related to a natural hormone, and the research on it comes from animal and laboratory studies.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no product containing it authorized in the European Union.1 FDA found no studies of KPV in people at all, so its effects and safety in humans are unknown.1 FDA staff recommended against adding KPV to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6
| What it is | A peptide of three amino acids: lysine, proline and valine. Research FDA reviewed describes it as the end segment of alpha-melanocyte-stimulating hormone.1 |
|---|---|
| FDA status | Not FDA-approved. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, KPV acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6 |
| Human evidence | None found. FDA identified no clinical studies or other human exposure data for KPV.1 |
| Evidence strength | Animal and lab studies only. The cited sources report no completed human study; the research base consists of animal, cell, or other laboratory work. How this label is assigned |
KPV is a small peptide made of three amino acids: lysine (K), proline (P) and valine (V). Research FDA reviewed describes it as the final three amino acids of alpha-melanocyte-stimulating hormone (α-MSH), a natural hormone with anti-inflammatory effects.1
FDA could not determine how long or how widely KPV has been used in compounding. Outsourcing facilities reported no products containing it from 2017 to June 2025.1
FDA found websites promoting KPV for inflammatory and gut conditions, wound healing and skin health, sometimes combined with other peptides such as BPC-157 and TB-500.1
How KPV works has not been established. FDA’s briefing states that the molecular targets behind its reported effects remain unknown.1
Unlike the full hormone it comes from, KPV did not appear to act through the hormone’s usual melanocortin receptors in laboratory studies. Researchers have proposed that it may dampen inflammatory signaling inside cells instead.1
FDA found no pharmacokinetic studies showing how KPV is absorbed or handled by the body.1
There are none in FDA’s review. FDA evaluated KPV for wound healing and inflammatory conditions and found no clinical studies or other human exposure data for KPV by any route.1
The nine references submitted to FDA in support of KPV were animal studies of related hormone fragments and one laboratory study in donated human skin.1
FDA’s searches of its adverse-event databases through December 2025 found no reports involving KPV.1
FDA concluded that there is a lack of evidence to evaluate whether KPV works for the proposed uses and that its safety risks in people are unknown.1
Evidence-strength label: Animal and lab studies only. How this label is assigned
No. FDA’s May 2026 evaluation states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.1
Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5
FDA staff evaluated both forms of KPV for that list for wound healing and inflammatory conditions and recommended against adding either. They cited poor chemical characterization, unknown extent of use, no human data on safety or effectiveness, and existing FDA-approved treatments.1
FDA’s compounding safety-risk page, last updated April 22, 2026, lists KPV among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.3
HHS’s policy document states that KPV was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6
FDA’s Pharmacy Compounding Advisory Committee discussed KPV on July 23, 2026. HHS’s policy document states that the committee voted in favor of including it, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6
On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6
Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For KPV, the policy covers only the acetate salt form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6
HHS and FDA staff weigh the same record differently. HHS’s policy document says use of KPV is now documented, that newer test results for the acetate form supply what FDA staff found missing, and that FDA staff’s safety conclusion reflects an absence of information rather than an observed harm. FDA staff had found no human data at all.1,6
The policy does not make KPV an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6
Whether KPV has any benefit in people: FDA found no human studies of it for any condition.1
Its safety in people, how it is absorbed, and whether it can trigger immune reactions.1
What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that inconsistent naming is a safety risk.1
Whether FDA’s rulemaking will add KPV to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for KPV: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for KPV are the records PeptideScanner has selected and published, not every registration or paper about KPV. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Evidence summary
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
FDA assessment dated May 12, 2026 · Read September 15, 2026 · Preserved version 1
FDA's assessment of KPV free base and KPV acetate for the nominated uses of wound healing and inflammatory conditions. The assessment was prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting. FDA document ↗
FDA reported that its search did not identify studies of KPV administered to humans. It concluded that evidence was insufficient to evaluate effectiveness for the nominated uses. FDA pp. 20, 21 ↗
FDA identified a skin-permeation study using human cadaver skin among the nomination references. That is not a study of KPV treatment in living participants. FDA pp. 20 ↗
FDA reported no identified human pharmacokinetic studies or clinical safety studies. Its adverse-event searches through December 3, 2025 did not identify qualifying reports; the agency states that potential safety risks in humans are unknown. FDA pp. 25, 26 ↗
This summarizes the agency's dated assessment. It is not an independent claim that no evidence exists worldwide or that the briefing is a final regulatory decision. Newer reports and formulation identities require separate screening.
Source: FDA briefing document for KPV. SHA-256: 0253b86534700fc72a48cccab7b10c19201102da831ef7a8a28e8dab09fea254.
Reviewed 2026-09-19 · Preserved version 1
FDA’s July 2026 briefing found that the submitted references concerned animal work or skin permeation using human cadaver skin. These are distinct from administering KPV to living participants. FDA PDF pp. 20 ↗
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
FDA reported finding no clinical studies supporting KPV for wound healing or inflammatory conditions in its evaluation. This is an attributed search finding, not proof that no relevant record could exist anywhere. FDA PDF pp. 20, 21 ↗
The briefing found no human pharmacokinetic or clinical safety studies. Its adverse-event search retrieved no reports, but FDA explicitly explains why passive reporting cannot establish safety. FDA PDF pp. 26 ↗
FDA identified missing characterization and formulation data and insufficient information about aggregation and immunogenicity. A three-amino-acid sequence alone did not resolve those product-level questions. FDA PDF pp. 27, 28 ↗
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
Source dated 2026-07-23; retrieved 2026-09-19.
SHA-256: 0253b86534700fc72a48cccab7b10c19201102da831ef7a8a28e8dab09fea254
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Open machine-readable coverage and record decisions →
Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.
128 retrieved · 0 included · 128 excluded · 0 awaiting a decision · 0 full-text appraisals
"KPV"[Title/Abstract] OR "Lys-Pro-Val"[Title/Abstract]
Retrieved 2026-09-15T13:04:50.086500+00:00 · HTTP 200 · SHA-256 eaa4d3fe4ab20414a5ead879b11a0179d951450d9b5a19612bbb6a32cf71f36e.
Retrieved 2026-09-15T13:04:52.499645+00:00 · HTTP 200 · SHA-256 baf3e40647c186121cfab1332e29f62ac68da0eda8b7552c5f50fc58597513a1.
Showing 25 of 128 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Read the source full text ↗ · sections 2.5.4, 2.5.5.
This reading establishes eligibility for this search; it is not a full appraisal of the study.
Reviewed 2026-09-15; source SHA-256 7a3158245d0f6a0d4d23c128e6d9b41efb84e006120275de1deb364f466ceb1a.
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
products.active_ingredients.name:"KPV"
Retrieved 2026-09-15T11:10:16.981646+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["KPV", "Lys-Pro-Val"]
Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["KPV", "Lys-Pro-Val"]
Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Case-insensitive word-boundary identity terms: ["KPV", "Lys-Pro-Val"]
Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
"KPV" OR "Lys-Pro-Val"
Retrieved 2026-09-15T11:26:15.363786+00:00 · HTTP 200 · SHA-256 b54968c05ff881a1ef7ce604b6a340248f8e2aee8637bef06da0f5693f520df8.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
Living status brief
Not an FDA-approved drug. FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Regulatory · source date July 24, 2026
FDA committee met on seven peptide-related groups of bulk drug substances↗Added to PeptideScanner July 29, 2026Regulatory · added August 21, 2026
Federal Register notice 2026-07361↗Source date April 16, 2026Literature metadata · added August 12, 2026
PubMed record PMID 34846053↗Source date December 23, 2021Literature metadata · added August 12, 2026
PubMed record PMID 34547895↗Source date October 21, 2021PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.
0 of 11 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Bibliography fields unavailable here for 11 selected records; the records remain visible as metadata observations.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
We added a plain-language reader guide with cited answers, re-checked FDA’s KPV briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists KPV acetate. FDA has not issued a final 503A rule.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.
0 with attributed title, venue, publication-date, and type metadata.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span November 14, 2003 to July 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Regulatory
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗
Regulatory
The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 39252648 at 2026-07-30T16:25:12.445Z. PubMed recorded a metadata revision date of 2026-02-17 and an Entrez history date of 2024-09-10. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 27458604 at 2026-07-30T18:28:30.778Z. PubMed recorded a metadata revision date of 2025-05-30 and an Entrez history date of 2016-07-27. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 34846053 at 2026-07-30T19:56:20.406Z. PubMed recorded a metadata revision date of 2021-12-23 and an Entrez history date of 2021-11-30. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 34547895 at 2026-07-30T19:58:34.757Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2021-09-22. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 22837805 at 2026-07-30T19:58:22.828Z. PubMed recorded a metadata revision date of 2021-10-21 and an Entrez history date of 2012-07-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 25298219 at 2026-07-30T20:43:08.957Z. PubMed recorded a metadata revision date of 2019-12-10 and an Entrez history date of 2014-10-10. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 29953505 at 2026-07-30T21:09:28.939Z. PubMed recorded a metadata revision date of 2018-12-19 and an Entrez history date of 2018-06-29. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 18092346 at 2026-07-30T21:10:56.892Z. PubMed recorded a metadata revision date of 2018-09-13 and an Entrez history date of 2007-12-20. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 28343991 at 2026-07-30T21:12:28.720Z. PubMed recorded a metadata revision date of 2018-04-05 and an Entrez history date of 2017-03-28. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 15102092 at 2026-07-30T21:56:55.933Z. PubMed recorded a metadata revision date of 2013-11-21 and an Entrez history date of 2004-04-23. PeptideScanner associated this retained record with the identity slug kpv. These dates describe PubMed metadata history, not the article's original publication date.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register via GovInfo · Official source · Source checked August 21, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026